O ROURKE & COMPANY Inc Sells 5,398 Shares of Pfizer Inc. (NYSE:PFE)

O ROURKE & COMPANY Inc decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 33.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,651 shares of the biopharmaceutical company’s stock after selling 5,398 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Pfizer were worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC grew its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer in the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC grew its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the fourth quarter worth $36,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research reports. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, June 26th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $35.54.

Pfizer Trading Up 0.9 %

PFE stock traded up $0.24 during trading on Monday, reaching $28.22. The company had a trading volume of 24,982,110 shares, compared to its average volume of 40,791,203. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a market cap of $159.91 billion, a P/E ratio of -470.25, a PEG ratio of 1.10 and a beta of 0.69. The business has a 50 day moving average of $27.90 and a 200 day moving average of $27.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm earned $1.23 earnings per share. Pfizer’s revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.95%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.